UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

May 26, 2006

Lifeline Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Colorado

000-30489

(Commission

File Number)

(State or other jurisdiction of incorporation)

6400 S. Fiddler's Green Circle, Suite 1970, Englewood, Colorado

(Address of principal executive offices)

Registrant's telephone number, including area code:

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

84-1097796

(I.R.S. Employer Identification No.)

80111

(Zip Code)

720-488-1711

Item 8.01 Other Events.

Lifeline Therapeutics, Inc. filed Amendment No. 2 to Form SB-2 with the Securities and Exchange Commission on May 26, 2006. The filing is in response to comments made by the SEC following the filing of the Company's Amendment No. 1 to Form SB-2 filed on February 6, 2006.

The filing of this amendment is expected to clarify issues involved in the registration process.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

June 1, 2006

Lifeline Therapeutics, Inc.

By: Gerald J. Houston

Name: Gerald J. Houston Title: CFO